We went looking for a scale.
We found a diploma mill.
Rise was briefed as an app built on Dr. David Hawkins' Map of Consciousness. Research killed that version in a day, on three separate grounds: legal, evidentiary, and simple kindness to the user. What survived is a smaller, better, defensible product. This dossier is the argument for it.
Executive summary
Four findings. The first three close doors; the fourth opens a better one.
Finding 01 · The framework has no evidentiary base
The Map of Consciousness rests on Hawkins' 1995 doctoral dissertation, submitted to Columbia Pacific University, an institution shut down by California court order with findings that it had failed to meet the requirements for issuing PhD degrees.[7] The book that made it famous was published the same year by Hawkins' own imprint.[8] No independent party appears anywhere in that chain. It has never been peer-reviewed, replicated, or tested.
Finding 02 · The name is owned, and they will not license it
MAP OF CONSCIOUSNESS® is a live US trademark (Reg. 4,086,310), renewed 2021.[1] Veritas Publishing's policy states plainly that permission will not be granted to use it.[2] That is a refusal to license, not an opening bid.
Finding 03 · The brief contradicted itself
"Never judge the user" cannot coexist with "your score is 20 out of 1000." A ladder from Shame to Enlightenment is a hierarchy of human worth with a decimal point. And 18 levels cannot be shown as 18 large buttons to someone in deep apathy — the brief's own constraints ruled out the brief's own structure.
Finding 04 · Subtraction solves all three at once
Remove the numbers and the trademark, and the legal exposure, the psychological harm, and the need for a pseudo-science disclaimer all disappear together. What remains — name the state, see the movement, do one small thing — has a real evidence base underneath it.
It is rare that the safe move and the good move are the same move. Here they are.
What the framework claims
Described, not reproduced. This is analysis of a copyrighted work, so we cite it rather than copy it. Understanding the claim precisely matters, because the specific shape of the claim is what makes it testable, and what makes 30 years of non-testing significant.
The claim
Human consciousness can be assigned a number from 1 to 1000 on a logarithmic scale. Below 200 are "force" states — Shame, Guilt, Apathy, Grief, Fear, Desire, Anger, Pride. At 200 sits Courage, the threshold. Above it are "power" states, rising through Neutrality, Willingness, Acceptance, Reason, Love, Joy, Peace to Enlightenment.
Hawkins claimed these numbers were derived through muscle testing (applied kinesiology). That a binary arm-strength response could index any proposition against a universal database of consciousness. His publisher states the Map draws on over 250,000 calibrations across 30 years.[9]
Why the shape matters
This is not a vague spiritual metaphor. It is a specific, quantitative, cheaply falsifiable claim: give a practitioner a sealed envelope, have them calibrate what's inside, check the answer. An afternoon's work.
That's the crux of §03. A claim this testable, left untested for three decades, isn't merely unproven. The non-testing is itself the finding.
The claim, made tappable
Rendered for analysis, so §03 has something concrete to argue with. Our own layout and palette, not a reproduction of the copyrighted chart, and every level carries the evidential note the original doesn't.
One structural feature deserves naming: Hawkins held that skepticism itself calibrates below 200, in the "force" range. The system classifies the disposition required to test it as a low-consciousness state. That is an epistemically closed loop, and it explains the absence of engagement in §03 as a designed property rather than an accident.
Does it hold up?
Concede everything true first. It costs nothing and it is the only way the rest of this reads as analysis rather than a hit piece.
Granted, without grudging
David Hawkins was a real psychiatrist. MD from the Medical College of Wisconsin, 1953. Medical Director of the North Nassau Mental Health Center from 1956 to 1980. Roughly fifty years of licensed clinical practice. He genuinely co-edited Orthomolecular Psychiatry with Linus Pauling in 1973.[10] None of that is in dispute, and any analysis that fudges it deserves to be dismissed.
The credential ledger
| Claim | Status | What's actually true |
|---|---|---|
| MD, psychiatrist | ✓ Verified | Medical College of Wisconsin, 1953. ~50-year practice. Genuine. |
| Co-authored with Linus Pauling | ⚠ Qualified | Real, but they co-edited a volume, not a joint paper. And orthomolecular psychiatry was rejected by the APA the same year the book appeared: Task Force Report 7 (1973) found "the credibility of the megavitamin proponents is low."[13] Pauling and Hoffer contested it vigorously; the mainstream verdict held. |
| PhD | ✗ Diploma mill | Columbia Pacific University, 1995. Closed by permanent injunction of the Marin County Superior Court, 2 Dec 1999. Court findings included failure to meet the requirements for issuing PhD degrees. California's Deputy AG called it "a diploma mill which has been preying on California consumers for too many years."[7] |
| "Sir" David Hawkins | ✗ Not a knighthood | Conferred by a body not among the five mutually recognised Orders of St John, which describe all others as "self-styled." No state recognises it. The dates conflict even between Hawkins-friendly sources.[14] |
| Nobel nomination | ◇ Doesn't exist | Nobody claims one. The publisher claims a Templeton nomination — unverifiable in principle, since the Foundation doesn't publish nominees. The Nobel association is transitive, via Pauling. |
| AMA award, APA fellowship | ⚠ Misleading | The AMA "Physicians Recognition Award" is a continuing-education participation certificate. The APA fellowship is a tenure-based membership grade. Neither is a scientific honour. |
| Undergraduate institution | ? Unresolved | Publisher says Milwaukee State Teachers College; third parties say Marquette. Sources conflict. We assert neither. |
The provenance chain, the finding that requires no argument
The "research" behind the Map is the Columbia Pacific dissertation. Power vs. Force was published the same year, 1995, by Veritas — Hawkins' own imprint.[8]
So the complete evidentiary base is: a dissertation from a court-closed diploma mill, plus a self-published book. There is no independent link anywhere in that chain. You don't have to adjudicate a single question about muscle testing to see the problem.
The 60/50 contrast
Here is the most informative pattern in the whole literature, and it is fatal in a quiet way. Muscle testing performs above chance in exactly one condition, and it is the one condition Hawkins' claim never occupies.
🧪 When the subject knows the answer
Anne Jensen's Oxford work, a DPhil, blinded, randomised, replicated across a decade. Practitioners judged whether a person's own spoken statement was false: 65.9% and 59.4% accuracy versus ~50% for intuition, p<.01.[4] Replicated in PLoS One 2025 at 61.6%.[5]
This is the real steelman and it must be reported. But note what the task is: the person being tested already knows whether they're lying.
🎯 When nobody knows the answer
Sealed vials — saline versus a toxin. Everyone blinded. 51 participants, 151 test sets. Correct 80 times out of 151: p = .258. Chance. Both kinesiologists performed, in the authors' words, almost exactly at chance.[3]
The authors were on muscle testing's side. Schwartz researches nonlocal consciousness; Utts is a statistician known for sympathetic readings of parapsychology. They built the study to find the effect. This forecloses the "skeptics rigged it" reply.
Why that contrast settles it
Hawkins' claim lives entirely in the second condition — calibrating facts nobody present knows, and in many cases nobody knows at all. Nothing in this literature bridges "60% at detecting whether you're lying about your own sentence" and "accesses a universal database to rank a book, a person, or an idea on a 1–1000 logarithmic scale." That isn't a difference of degree, and no proponent has attempted the bridge.
Jensen's own data point the same way. Her 2025 variance decomposition found the test patient explained 35.4% of accuracy variance; the practitioner only 21.6%.[5] The effect tracks who is being tested, not who is testing, which is the signature of a response originating in the person who already knows the answer.
The wider applied-kinesiology literature
| Study | Design | Result |
|---|---|---|
| Lüdtke et al. 2001[6] Complement Ther Med |
7 patients with independently confirmed wasp-venom allergy; 4 examiners; fully blinded; 800 test events | κ = 0.03 No better than guessing. There was a real ground truth to find; they couldn't find it. |
| Soares et al. 2025[12] J Manipulative Physiol Ther |
Systematic review, 8,720 records → 7 studies | "Nonexistent reliability" Published in a chiropractic journal. Inter-examiner κ ranged −0.51 to 0.91 — worse than chance, to strong. |
| Haas, Cooperstein & Peterson 2007[15] Chiropractic & Osteopathy |
Critical analysis | The key distinction Ordinary muscle testing is valid, for measuring muscle strength. Applied kinesiology borrows that credibility for diagnostic claims it hasn't earned. Severing this inference is the whole game. |
| Professional bodies | Position statements | Unanimous rejection ACAAI (2008): "no evidence of diagnostic validity." Also AAAAI, EAACI, NICE, the American Cancer Society. The Danish Chiropractic Association formally disowned it in 1998 — chiropractors themselves. |
Note for anyone extending this research: no Cochrane review of applied kinesiology exists. Don't cite one.
The mechanism, and the right disposition
🕯️ Faraday got there in 1853
The ideomotor effect was named by Carpenter in 1852 and built specifically to explain dowsing rods and table-turning — 112 years before applied kinesiology existed.[16] Faraday settled it by slipping a card between the sitters' hands and the table: the hands moved first. They were pushing — sincerely, and without any awareness of it.
That is the structure here exactly. The ideomotor account requires nobody to be lying, which is why it fits both the null results and the practitioners' entirely genuine conviction.
⚠️ The cautionary tale that already ran
Facilitated communication is the closest analogue we have. Sincere, trained, credentialed facilitators produced fluent speech from non-verbal autistic people. Everyone believed. Then controlled testing showed the facilitators were authoring every word, with no awareness whatsoever.[17]
Same mechanism, same sincerity, same confidence. It caused real harm before it collapsed. Unlike applied kinesiology, its collapse is settled history.
The disposition throughout should be Faraday's, not Randi's: the practitioners are sincere, the arm really does go weak, and the attribution is still wrong.
The IP position
Researched before a line of code was written. Good thing.
What's actually protected, and what isn't
| Element | Status | Reasoning |
|---|---|---|
| The name "Map of Consciousness" | Trademarked | Live registration, renewed. Don't use it, not in the app, not in marketing, not in the store listing. |
| The chart, its layout and visual form | Copyrighted | Registered work. Don't reproduce it. |
| Hawkins' per-level prose | Copyrighted | And paraphrasing is still infringement, which is the trap the original brief walked into by asking for "typical behaviours and self-talk" per level. |
| The 18 numbers as a selected, ordered set | Grey | Facts aren't copyrightable, but a selection and arrangement can be protected as a compilation. Genuinely uncertain, and Veritas is plainly willing to litigate. |
| The idea of an emotional spectrum with a threshold of agency | Free | Ideas and systems are excluded from copyright outright. |
| "Letting go" — allowing an emotion rather than fighting it | Free | Not his. It predates him in Buddhism, in ACT, and in Gendlin's Focusing. See §05. |
The decision that had already been made
The call to de-emphasise the number was taken on design grounds, before any of this research existed. It turned out to do almost all of the legal work too.
The numbers are simultaneously the most legally exposed element, the most psychologically harmful element, and the least necessary element. Deleting them resolves three problems with one stroke, and takes the disclaimer with it, because once you aren't claiming a muscle-tested logarithmic scale, there is nothing left to disclaim.
⚖️ Not legal advice, and nobody here is a lawyer. If we ever go near the Hawkins audience as a wedge, that needs a real opinion from a real attorney before submission.
What's actually real
The evidence base that could ground Rise, now that the Hawkins layer is gone.
Read this first · four of our seven premises did not survive
We asked for evidence rather than confirmation. We got it. This section damages the model proposed in §07, and that is the section working as intended.
| Premise | Verdict | What's actually true |
|---|---|---|
| Anger is a recovery signal | ✗ Refuted | Evidence runs the opposite way. See below. Cut it. |
| Affect labelling "name it to tame it" |
✗ Possibly backwards | Lieberman 2007 measured no feelings at all — it's a BOLD-signal study, and participants labelled other people's faces.[34] Where felt distress was measured: 0.39 points on a 9-point scale, about 6%.[35] In the best behavioural test, self-reported fear showed no difference.[36] And it's worse than oversold. The best-replicated causal finding is that labelling impedes regulation: naming an emotion before reappraising made people feel worse, d = −1.21, replicated at N=226. Naming may "crystallize" an emotion and make it more resistant to modification.[55] The dose–response runs backwards: people who used fewer labels improved more.[56] And no meta-analysis of affect labelling has ever been published — confirmed five ways. Any "meta-analyses show d = X" claim is unsupportable. |
| Behavioural activation | ⚠ Yes, but | The strongest evidence we have — for full protocols. BA equals antidepressants (bioequivalence p>99.1%) and equals CBT (Cochrane, 53 RCTs, RR 0.99).[37] But nothing in this literature tests a micro-action. The smallest tested unit is one 60-minute session. Our feature is three extrapolations past the data. Say "BA-inspired," not "evidence-based BA." |
| Emotion granularity justifies naming states | ✗ No causal evidence | The authors explicitly warn that closed-ended emotion menus don't capture the construct: you "must assess what is being felt without using prompts with a closed-ended list of emotion-word labels."[38] We cited this paper to justify a design it says doesn't measure the thing. Worse: there is no causal evidence at all. Four randomised studies raise the differentiation index; two tested whether the gain tracked outcomes and found null, one couldn't test it, one collected the outcomes and didn't report them.[57] A 2026 multiverse analysis found the granularity–depression correlation "not robust in any of the data sets" — and in one dataset every correlation ran the opposite way, 40% significantly so. The review's headline percentages don't survive checking either: the "30% more strategies" figure does not appear in its source. |
| Suppression is harmful, so allow the emotion | ⚠ Shakier than assumed | Conflates three different constructs. Expressive suppression is correlationally bad in Western samples only, the effect vanishes in Hong Kong Chinese participants, which matters for an India-facing product. Thought-suppression rebound has "poor replicability… likely influenced by publication bias." And trained retrieval suppression improves mental health, with the largest gains in high-anxiety and probable-PTSD users.[39] Ground "letting go" in ACT's own trial data, not the white bear. |
| Russell's circumplex as a structure | ✗ Not lawful | Russell and Barrett published the disconfirmation themselves: "casts doubt on the existence of a static, lawful relation between valence and arousal."[40] And numbness and grief don't map onto it — grief is a process, not a point; numbness may be the absence of affect rather than a location in it. |
| Daily mood tracking helps | ✗ No evidence | See the block below. This is the finding that could sink the product. |
§12.01 answered · the anger claim is refuted, and it's a safety issue
Judd et al., JAMA Psychiatry. N=536, NIMH Collaborative Depression Study, prospective follow-up up to 31 years. Overt irritability or anger was present in 54.5% of depressive episodes, and it was associated with greater severity, longer episodes, poorer impulse control, more comorbid substance abuse, and a more chronic course. Their conclusion: anger is "a highly prevalent clinical marker of a more severe, chronic, and complex depressive illness."[41]
Jha et al., Am J Psychiatry. N=431, replicated in a second sample. A one-SD reduction in irritability by week 4 predicted 1.73× higher remission at week 8. Anger leaving predicts recovery. Anger arriving predicts the opposite.[42]
The folk version — "energy returns before mood, so activation signals recovery" — has been examined and rejected outright: "As superficially appealing as the long-held mobilization-of-energy hypothesis is, it has little in the way of evidence to substantiate it."[43] It most likely descends from Kübler-Ross's "anger stage," which was never empirically demonstrated.
Why this is a safety issue and not just an accuracy issue. An app that tells a depressed user their anger means they're improving is reframing a marker of chronicity as progress, in a population with compromised impulse control. That could delay help-seeking. What we can defensibly say instead: anger is common in depression, roughly 30–55%, and it is not shameful. That is supportable, and it probably serves the user better anyway.
§12.02 answered · mood tracking has no demonstrated benefit, and nobody looked for harm
It doesn't help. A 2026 meta-analysis of 8 RCTs and 1,230 participants: mood monitoring "does not increase or decrease mood symptoms."[44] And when someone ran the head-to-head, a pure tracking app against two CBT apps, N=226 — only the CBT apps reduced depression. The tracker did not.[45]
And nobody adequately looked for harm. Across 77 studies and 16,165 participants: only 19% reported adverse events at all, only 17% assessed mood deterioration, and only 4% used a validated instrument to look.[46] The authors: "harm, safety, and usability are not given the priority expected for devices used in people with serious mental illness."
Two asymmetries make this live rather than academic. First, the standard laboratory rumination induction asks people to "focus on the meanings, causes, and consequences of their current feelings", a fair description of a reflective check-in, and it worsens mood in dysphoric participants but not healthy ones.[47] The harm concentrates exactly where our users are. Second, in MONARCA II, quality of life and perceived stress improved while depressive-episode risk rose.[48] Our standard product metrics would have scored that a win.
Be precise about what this does and doesn't say. "Mood tracking harms users on average" is not supported. "There is no evidence of harm" is true but hollow, because nobody looked. "There is evidence of no harm" is false. And "mood tracking may harm some users" is weakly but consistently supported, and never contradicted.
The design lever that survives
Rumination is the potent form of self-focus; non-ruminative self-focus is much weaker.[49] The induction that causes harm is open-ended dwelling for eight minutes. A check-in that is brief, bounded, forward-looking, and terminated by an action is a structurally different thing.
That is the argument for the §07 shape — two taps, under fifteen seconds, ends on one small doable thing, and it is now the main argument for it. Not gentleness. Rumination control.
A second, independent argument arrived by accident. Vine et al. randomised 82 people to minimal versus exhaustive emotion labelling: "Minimal (vs. exhaustive) emotion labelling promoted higher subjective emotional clarity", and prompted more plans for problem solving.[58] Two taps and one pick is the minimal condition. The constraint we adopted because the low-energy user demanded it turns out to be the one the evidence supports. How We Feel's 144-word Mood Meter is the exhaustive condition.
And if we instrument rumination pre/post, we'd be running the study the field has never run. That's both a genuine contribution and a genuine liability shield.
Correction · we had this backwards, and §12.02 is less binary than stated
An earlier draft of this section warned that "median day-30 retention across 93 mental-health apps is 3.3%". That number is real, and the framing was wrong. 3.3% is roughly the all-app median. Mental-health apps retain better than Social (2.45%) and Education (1.69%). Mood trackers specifically retain 6.1% — nearly double the category median, and better than meditation. Daylio retains 37.7% at day 30.[67] "Mental health apps don't retain" is an argument anyone with an AppsFlyer login dismantles in one meeting. It's cut.
And the efficacy picture is better than §12.02 implied. Linardon et al., World Psychiatry 2024, 176 RCTs: apps produce significant improvement — depression g = 0.28, anxiety g = 0.26, OCD g = 0.51, NNT ≈ 11–12. And mood monitoring features specifically are associated with larger effect sizes.[68]
That doesn't contradict the 8-RCT null above. It reframes it. Mood monitoring alone does nothing (Wright 2026). Mood monitoring inside an app that then does something works (Linardon 2024). The tracking isn't the intervention — it's the trigger for one. Which is precisely the §07 shape: a check-in that terminates in an action. §12.02 is therefore not "does tracking help" but the narrower, answerable "does our check-in reduce rumination while it triggers the practice?"
The honest one-line summary of this whole section: these apps work, almost nobody uses them, the ones who use them don't pay, and the ones who paid are leaving. Efficacy is not the bottleneck. Distribution and monetisation are — and that is a harder problem than product design solves.
The design problem
Two things in the brief cannot both be true. This is the section that changes the product.
🪜 A ladder always judges
Shame at the bottom, Enlightenment at the top, and the depressed user on the bottom rung. No amount of soft typography changes what that structure says. Telling someone in a depressive episode that they scored 20 out of 1000 is the most judgmental act an app can perform.
De-emphasising the number helps. But the ladder is still underneath it.
🔢 18 options is not "extremely simple"
The brief asks for a scrollable map of 18 levels and for maximum four questions, huge buttons, under fifteen seconds, usable in deep apathy.
You cannot show 18 large buttons. The brief's own constraints rule out the brief's own structure. Something had to give.
The reframe
Stop measuring the person. Start measuring their room to move.
Not worth. Not elevation. Not consciousness. Just: how much room do you have right now, from none at all, to wide open. That isn't a verdict on who someone is. It's a weather report. And weather changes, which is the entire premise of the app.
It also keeps the one genuinely useful idea in the source material: that there's a threshold where you stop feeling life is happening to you and start feeling you have a hand on the wheel. That's the crossing-200 celebration, intact, but now it's crossing the line where you get your hands back.
The proposed model — try it
Four zones, twelve states, two taps. Never more than four buttons on screen. This is live, not a mockup. Tap through it.
🪦 Why Churning ranks above Heavy — retracted
The original argument: anger above numbness lets Rise say something true and kind that no other mood tracker says, this is movement, not failure. It was flagged for verification rather than assumed.
The verification came back negative. Anger in depression marks a more severe and more chronic illness with poorer impulse control, and it is anger leaving, not arriving, that predicts remission (§05).
The claim is cut. The demo still orders Churning above Heavy; that ordering now has no evidential basis and is an open question for the review. What survives is narrower and still worth saying: anger is common in depression, and it is not shameful.
➖ The line
The threshold between Churning and Steady. Below it, things happen to you. Above it, you have a hand on the wheel. Crossing it is the celebration moment the brief asked for — without a single number attached.
Note what the demo never does: score you, rank you, or compare you to anyone.
Alternatives considered and rejected
| Approach | Case for | Why not |
|---|---|---|
| Two-axis mood field Russell's circumplex |
Empirically the strongest model of affect. No ordering at all, so nothing can rank the user. | With no ordering there is no "one small shift." The tagline dies, and with it the reason to open the app tomorrow. |
| Flat ordered list of 12 states | Simplest possible build. | Back to a ladder, and twelve options at once is still too many for a low-energy user. |
| Keep the numbers, shrink them | Closest to the original brief. | Keeps every legal risk and every psychological problem, in a smaller font. |
Market & competition
Including the uncomfortable question: is this a red ocean we should stay out of?
The finding · a brand moat, not a resource moat
We expected a red ocean full of funded competitors. That isn't what's there. Moodfit has exactly one employee and no verified funding at all, and has been shipping for a decade on that.[22] Stoic is nine people in Kraków on a single $150K Y Combinator seed from 2019, with no round since.[23]
These incumbents hold their position through ratings and time-in-market, not capital. A 4.8 with 35,000 ratings is a real moat. It is not a moat that spends money to defend itself.
| Moodfit | Stoic | |
|---|---|---|
| Entity | Roble Ridge Software LLC · Palo Alto | Stoic app inc. · Kraków, not San Francisco |
| Team | 1 person | 9 people |
| Funding | None verified | $150K YC seed, 2019 |
| iOS | 4.7 · 2,209 ratings | 4.8 · 35,007 ratings |
| Android | 4.0 · 855 · 100K+ installs | 4.5 · 3.03K · 100K+ installs |
| Free tier | 2 of 12 features | Prompts + basic journals |
| Lifetime | $119.99 (was $99.99), sold off-store to dodge Apple's 30% | $199.99 (estimate) |
| AI | None found | Second stacked paywall, token-metered |
| Killer risk | Bus factor of 1 | Data loss, no recovery path |
🎯 The wedge · both are squeezing their free tiers
Moodfit moved Gratitude out of Free and into Premium some time between February and May 2026. We can prove it from Wayback snapshots. It shipped with release notes reading only "Improved user experience and bug fixes."
Users noticed. One 1★ review: "You started charging for gratitude!!!! Why???? After years of logging this is what you do?" In 2020 the same app was being praised for being "the best free mental health tool I've ever come across."
Stoic draws 15+ paywall-aggression complaints. Both are converting long-time advocates into 1★ reviewers. A credible, stable free tier and honest pricing is an actual opening.
💀 Stoic's latent scandal
Backup is paywalled. Sync is iCloud-only, so Android subscribers pay the same price for a product missing its flagship feature by design. Stoic runs no servers, and their own documentation states they "cannot access or recover your data."
There are 8+ data-loss reports, acknowledged in their own changelog. A 5★ review, which is somehow worse than the 1★ ones: "if I had realized this 3 years ago and known how much those entries would mean to me today I would've thought twice about using Stoic."
For a journaling product, losing someone's journal is unrecoverable brand damage. Rise being offline-first and local-only must not inherit this failure mode. That is a design requirement, not a nice-to-have.
The finding that decides it · framework apps don't work, clinical ones do
We checked the adjacent consciousness-framework categories as a proxy for whether this kind of app has any demand at all. The answer is unambiguous.
The official Abraham-Hicks app is dead: both store links on their own homepage return 404, delisted globally.[24] Spiral Dynamics has zero apps, across both stores, in twenty years; the community's own assessment tooling is a Google Sheet.[25] Integral Life, Ken Wilber's own company, has 205 ratings, a delisted Android app, an iOS build untouched for 25 months, and no link to its own app anywhere on its own website. The Secret Super App has 203 ratings, on the back of 30M+ books sold. Total venture funding into the entire manifestation category: one round, ever, for $3.4M.
Now the other column. Noom raised roughly $657M on a CBT curriculum and holds 868,376 ratings. Tony Robbins' "The Path" raised $14.3M in May 2026 by repositioning from motivation to clinical AI therapy, while his own eponymous framework app sits at 2,283. "I am", an affirmations app, has 721,839 ratings, is bootstrapped, and licenses no framework at all.
The framework was never the asset. This is independent confirmation of the §04 decision, arriving from a completely different direction: dropping Hawkins isn't only the legally safe move and the kind move, it's the only version of Rise with any demand evidence behind it at all.
§12.03 answered · the market isn't closed by count, it's closed by economics
First, two stats everyone cites don't survive being pulled. The famous "CAC rose from $150 in 2018 to $500–1,000," universally attributed to Rock Health, is not Rock Health research. It is a Cerebral cofounder's verbal guess at a Jefferies investor event, reported by Business Insider, which Rock Health then paraphrased inside quotation marks and hyperlinked to a source saying something different. He was talking his book while his company was under DOJ investigation.[59] And "10,000–20,000 mental health apps" is 325,000 × 7%, where the 7% traces to a paper that doesn't contain it. Torous, the researcher everyone credits, says plainly: "There's no exact number… certainly it's more than a thousand. It's less than 20,000." A 20× uncertainty band.[60]
Now the audited evidence, which is worse than the folklore. BetterHelp, the largest advertiser in virtual mental health by its own CFO's description, spends ~55% of revenue on advertising — up from 48% in 2023 — and is still shrinking: revenue $1.13B→$950M, paying users 457K→386K, adjusted EBITDA down 69% in two years. Talkspace raised ad spend 120% in 2021 and lost 19% of its consumer members; by 2024 its advertising expense exceeded its entire consumer revenue.[61]
And the distribution is a wall. 52% of Google Play apps never reach 1,000 lifetime downloads. Only 7.9% of Health & Fitness apps ever pass 50K. About 65% of downloads require someone to search for you first. Releases are up 60–104% year-on-year in 2026, because AI codegen removed the build barrier. And the last time anyone measured it, a clinically relevant depression app went dark every 2.9 days.[62]
But here is the actual wedge, and it comes from Torous' own group: app stars and downloads — even for the most popular apps by those metrics — "did not correlate with more clinically relevant metrics related to privacy/security, effectiveness, and engagement."[63] The market cannot tell good from bad. The incumbent's answer is to outspend everyone, and that is failing in public. The opening isn't a cheaper app. It's being the one that can prove it works — which is exactly what §12.07 proposes.
The actual red-ocean proof · concentration, not count
Forget the app count. In mood tracking, the top three apps hold 79.2% of all monthly active users, and six apps hold 90%.[69] Across mental-health apps generally, Headspace and Calm alone account for roughly 90% of total MAU. We would not be entering a market. We'd be competing for the ~10% residue six incumbents haven't taken.
And the observed ceiling for a pure-play mood tracker is about $1.8M a year. That's Daylio — the category leader, bootstrapped, after a decade and 19.2 million downloads.[70] Two independent methods (bottom-up from conversion × LTV, and top-down from category share) converge on a defensible SOM of $150K–$2M/year. Finch is the outlier at a claimed ~$35M — but every figure for it is unsourced or panel-derived, it's ambiguous whether those are US-only or global, and Finch is a gamified virtual pet, not a mood tracker. Planning against it is survivorship bias.
Three plans the evidence kills before we make them
Don't win on gamification. Two meta-analyses find no effect (n=8,110, β=−1.93, p=.40; and n=16,728: "no significant association was found between persuasive principles and either efficacy or engagement"). And in the only head-to-head panel data, the least-gamified app (Daylio, 37.7% D30) retains twice the most-gamified one (Finch, 18.2%).[71] The pet is marketing. The tracker is the asset.
Don't win on reminders. A January 2026 meta-analysis of 77 studies and 17,123 participants found reminders decreased adherence and increased attrition.[71] If the retention plan is "notify them," the literature says it backfires.
Treat AI as a liability line, not a feature line. RevenueCat's 2026 data: AI apps churn 30% faster and retain 36% worse over twelve months, while earning +41% revenue per payer.[70] That is the quantitative version of what How We Feel's users are saying qualitatively (§08). It buys revenue and pays for it in churn.
What we could not find out, and won't pretend otherwise
Reddit sentiment research did not run at all. The sanctioned scraping path (Apify) is blocked: the account is on billing hold for outstanding invoices, and Reddit refuses direct fetches. So r/ADHD, r/bipolar, r/anxiety and r/Stoicism were never searched. That is the biggest hole in this section.
Also unresolved: Moodfit's Android 4.0 versus iOS 4.7 gap is real in the numbers but unexplained. Releases are two days apart with identical notes and every bug class appears on both platforms. We found no Android-specific defect. Any causal story here would be invention, so there isn't one.
Safety & compliance
Every rule below was verified against the primary source — Apple's and the FDA's actual documents, fetched and searched. Two widely repeated claims turned out to be false.
Myth 01 · "The App Store requires crisis resources"
It doesn't. Searching three versions of the App Review Guidelines spanning a year — June 2025, February 2026, and the live June 2026 text — returns zero occurrences of "suicide," "self-harm," "crisis," "hotline," or "mental health."[18] There is no rule.
The affirmative evidence is stronger still. Of 302 mental-health apps studied, only 15% referred users to 988, and 14 apps with over 3.5 million downloads shipped broken crisis hotlines and stayed on the store.[11] No reviewer practice can be missing 85% of cases and failing to notice a dead phone number.
So: ship 988 because it's right, not because anyone checks. And if we ship it, keep it working, a dead crisis number is worse than none.
Myth 02 · "Mental health apps are 17+"
17+ no longer exists. Apple replaced the tiers in July 2025 with 4+, 9+, 13+, 16+ and 18+; the deadline to re-answer passed 31 January 2026.[19] There is no self-harm or mental-health question in the questionnaire at all.
A pure mood log is defensibly 4+. Add self-care tips and you hit a 9+ floor. 18+ is unreachable for a mood app — it's gated on substances, sexual content, realistic violence and gambling. The 17+ belief is a stale pre-2025 artifact.
🏥 FDA — we're general wellness
Under FDA's General Wellness: Policy for Low Risk Devices (re-issued January 2026), FDA does not intend to examine low-risk general wellness products.[20] Their own worked example is a tracking app that "may help living well with anxiety."
A second safety net exists independently: FDA's mobile-app guidance expressly names enforcement discretion for software helping people with diagnosed depression maintain coping skills via a "Skill of the Day."[21] That is close to exactly what Rise does.
🚫 The line we must not cross
Verbatim from FDA's list of what is not general wellness:
"A claim that a product helps treat an anxiety disorder."
The trigger is claims, not subject matter. Rise may track, name, and support. Rise may not treat, diagnose, or score. Everything hangs on that verb.
The real risk edge · scored clinical instruments
A PHQ-9-style scored questionnaire with cutoffs is precisely where "wellness" becomes "diagnosis." It's where FDA's 2026 "diagnostic thresholds" exclusion bites, and where Apple's 1.4.1 finally becomes relevant — because 1.4.1 is about measurement accuracy and unsourced health claims, which a mood log otherwise never triggers.
Rise must not ship a scored clinical instrument without a deliberate, recorded decision. This is the single most important compliance line in the document, and it's one the original brief was drifting toward with its 1–1000 score.
The correction · we had the crisis trigger backwards
Early in this project the advice was that the brief's safety trigger fired too late, and that someone in a very low state needs the resource on day one rather than day nine. The evidence says that instinct is the dangerous one. The documented harm sits in the response, not the detection.
Over-escalation trains users to lie. 70% of people who conceal suicidal ideation from their own therapist cite fear of practical consequences, chiefly involuntary hospitalisation, from disclosing even mild thoughts.[26] About 1% of 988 contacts result in an involuntary rescue; roughly 1 in 5 US adults believe it would. Deterrence doesn't need the intervention to be common, only believed possible.
The corrected principle: conflate less, respond proportionately. Not detect less, and not escalate faster.
Why threshold-triggered escalation cannot work
This is arithmetic, not engineering. No better instrument escapes it.
A national guideline already found this harmful
Do not use risk assessment tools and scales to predict future suicide or repetition of self-harm.
Do not use global risk stratification into low, medium or high risk to determine who should be offered treatment or who should be discharged.
NICE guideline NG225 §1.6.1, §1.6.4 (2022)[29]
NICE's own rationale: "the potential harms of risk stratification, including the implication that risk is static instead of dynamic, outweigh any benefits." 988's own policy points the same way: "least invasive intervention", involuntary action "only as a last resort."[30]
What to do instead · the design finding
Pisani's reformulation replaces the categorical high/medium/low judgment with risk state measured against the person's own baseline, rather than against a population.[31]
That is computable from longitudinal check-in data in a way population stratification is not, and it sidesteps the base-rate problem entirely. It also happens to be exactly what the §07 model already measures: movement relative to you, not position relative to everyone. The kind design and the safe design converge again.
Instrument licensing, if we ever ship one
| Instrument | Commercial app? | Detail |
|---|---|---|
| PHQ-9 | ✓ Free | Public domain since 2010. "No permission required to reproduce, translate, display, or distribute." Pfizer released it at no charge.[32] |
| C-SSRS | ✗ Contested | A trap. Clario holds an exclusive licence on electronic implementations at $40,000 start-up plus $4 per administration, while Columbia's own site says no permission is needed. An app is an electronic implementation. Do not ship without written clarification.[33] |
| ASQ | ⚠ Probably | NIMH says "free of charge" but publishes no public-domain declaration and no commercial terms. Questions may not be altered. Get it in writing. |
Also under-rated: Guideline 5.2.1, health content published under a seller name that isn't a "recognised institution." Better documented than the hotline myth, and worth a look before we pick a publisher entity.
US states · where the actual exposure is, and it has no size floor
Connecticut's Attorney General is investigating a mood-app analogue right now. Per their own 2026 enforcement report: a fertility-tracking app, opened because its "privacy notice failed to recognize Connecticut's heightened consumer health data protections" — and the AG "tested their app on both iOS and Android devices to review data flows."[64] Read what triggered it. Not a leak. The notice. A perfect architecture with a boilerplate privacy policy is exactly the fact pattern under investigation.
And size stops helping the moment you leave California. CCPA lets us out cleanly, and on a ground that requires winning no argument: its thresholds turn on "buys, sells, or shares", and an app with no network calls can never do any of those at any user count. But Washington's MHMDA, Connecticut, Nevada, and California's CMIA have no size thresholds at all.[65] "We're small" is not an answer to the laws that actually reach us. Washington is the weakest ground: its definition turns on what the data identifies, with no "use" element — so the defence that works in Nevada and Connecticut is unavailable there.
The one nobody asks about: California's CMIA. § 56.06(b) deems "any business that offers software or hardware to consumers, including a mobile application… designed to maintain medical information" to be a provider of health care. That is a near-verbatim description of Rise. No thresholds — and § 56.36(b) gives a $1,000 private action where "it is not necessary that the plaintiff suffered or was threatened with actual damages."[66] Three off-ramps save us, and one of them is the landing page: "mental health digital service" is a three-part conjunctive test, and a tracker marketed as journaling and self-knowledge fails prong two and escapes. Marketed as "get mental health support," it doesn't.
The pattern across every regime · what you say determines what you are
FDA: "a claim that a product helps treat an anxiety disorder" is the line, and the trigger is claims, not subject matter. India: the intended-use statement does all the legal work, because there is no wellness carve-out to hide behind. California's CMIA: the marketing copy decides whether we're a health care provider. Apple 5.1.1(ix) and 5.2.1: health content under a non-institutional seller name draws scrutiny. Connecticut: the notice opened the investigation.
Five separate regimes, one control. The marketing copy is compliance infrastructure, not decoration — and it is the cheapest control available to us. Everything else costs engineering; this costs a decision about what Rise claims to be. Rise tracks, names, and supports. Rise does not treat, diagnose, or score.
India · the exemption is real, but brittle
An offline, no-account app is almost certainly outside India's DPDP Act. But the defence is §3(c)(i), processing for a personal or domestic purpose, not "we never receive the data." §2(i) defines a Data Fiduciary purely as whoever "determines the purpose and means", with no receipt, access or custody element. On the bare text we would be a Data Fiduciary; §3(c)(i) is what makes that irrelevant.[51]
Which makes the exemption brittle in a way that matters to us specifically. Any egress at all collapses it: crash reporting, an analytics snippet, remote config, a dependency that phones home. That conflicts with the house rule to wire analytics at creation. Fine for this dossier, which is internal and holds no personal data. Not fine for the app, if India is a target market.
And one exposure architecture cannot shield: §9(2), no processing "likely to cause any detrimental effect on the well-being of a child", is non-derogable and un-exemptible, and it is a product-design standard rather than a data-handling one. Streak pressure, distressing trend charts, or no crisis off-ramp could be argued into it with perfect on-device isolation. Ceiling ₹200 crore. It commences ~May 2027, so there is runway, but it is a design constraint rather than a privacy-policy one.
EU · a mood diary is special-category health data. Named, explicitly.
The most on-point citation in this whole section is a footnote. The Article 29 Working Party's mHealth guidance gives, as its worked example of when quantified-self records become health data, an app combining years of tracking "as well as a mood diary" — and adds that in that case "not only the conclusions and inferences, but also the raw data will be considered health data."[52] Recital 35 closes the obvious escape: health data counts "independent of its source." Self-reported doesn't mean not-clinical.
So a longitudinal mood log is Article 9 data. A single isolated entry probably isn't. The distinction is the trend line, which is a feature we want.
And an assumption worth killing before someone builds on it: "we make no network calls, so ePrivacy doesn't apply" is false. The 2009 amendment deliberately deleted the network reference from Art. 5(3), and Recital 65 expressly contemplates software delivered on a USB key. A phone is terminal equipment because it could connect, not because it does.
The conclusion still converges with India, and for the same reason. The developer is very likely not a controller: no own purposes, no transmission, no recipient, no benefit. Article 3 is never reached, because both its limbs presuppose a controller. The architecture is the compliance strategy — and the moment an analytics SDK, crash reporter or cloud backup ships, we become a controller of Article 9 health data and explicit consent becomes mandatory.
US · "nothing leaves the device" is necessary but not sufficient
HIPAA doesn't reach us — no covered entity, no covered transaction, and OCR's own guidance answers this exact scenario ("consumer populates a health app with her own information") with a flat no.[53] That part is clean.
The FTC's Health Breach Notification Rule is where it gets counterintuitive, and it corrects the rule stated above. We are a "covered health care provider" under it — the rule expressly names a mobile application that "provides mechanisms to track… mental health." The mood data is covered information. Both elements are met. The only thing that saves us is that we're not a "personal health record", which turns on having "the technical capacity to draw information from multiple sources."
And "multiple sources" has nothing to do with network calls. The FTC's own example counts the phone's local calendar API as a second source. Their closest worked example is almost exactly this product: "a depression management app that accepts consumer inputs of mental health states and has the technical capacity to sync with a wearable sleep monitor is a personal health record, even if some customers choose not to sync." Capacity, not use. And they explicitly refuse to exempt unused, unpublicised, or beta integrations.[54]
So the engineering rule is stricter than "nothing leaves the device." It is: read only what the user types. Add HealthKit, sleep sync, step counts, or calendar context — even entirely on-device, even in dead code — and Rise becomes a personal health record carrying breach-notification duties it structurally cannot discharge: with no account, there is no address to notify anyone at. That is the worst of both worlds, and it is one dependency away.
Open questions for the weekend
Genuinely open. None of these are rhetorical, and two of them could still sink the product.
01 · Is "anger is recovery" true? Answered · no
Refuted, and cut from the product. Anger marks a more severe, more chronic course with poorer impulse control; anger leaving predicts remission (§05). The most distinctive thing Rise would have said turned out to be false and plausibly harmful. What remains for the room: does Churning still belong above Heavy at all, now the rationale is gone?
02 · Does tracking help or harm? Answered · neither, and nobody looked
No demonstrated benefit (8 RCTs, 1,230 people, null; a tracking-only app lost head-to-head to CBT apps). Harm essentially unmeasured — 4% of studies used a validated instrument to look. The rumination induction is a reflective check-in, and it worsens mood in dysphoric users specifically (§05). This is now the biggest live risk in the project, and a genuine shelve-or-proceed question.
07 · Do we run the study nobody has run?
No RCT has ever randomised users to mood tracking and measured rumination as an outcome. If Rise instruments rumination pre/post, we answer the field's open question, defend ourselves against the harm case, and own a claim nobody else has. That may be a better wedge than any feature in the brief.
08 · Does the closed-list picker survive?
The granularity research we cited to justify naming states says closed-ended menus don't capture the construct — free text does. But free text costs the low-energy user real effort, and that user is the entire design constraint. Genuine tension, no clean answer.
03 · Is the market closed? Answered · not by count
The saturation stats are folklore — the famous CAC figure is a Cerebral cofounder's guess at a bank conference, and nobody has ever counted the apps (§08). But the economics are genuinely hostile. BetterHelp spends 55% of revenue on ads and is still shrinking; 52% of Play apps never reach 1,000 downloads. The opening is that the market cannot tell good from bad — stars and downloads don't correlate with efficacy. Which points straight at 07.
04 · What's the smallest thing worth shipping?
The check-in in §07 plus one practice plus a trend line is perhaps three days of work. Everything else in the brief — journal, voice notes, achievements, education — is a later ring.
05 · Does Rise need an agentic layer at all?
House rule says every product is agentic-AI-first with a voice widget. This brief says offline, no login, no AI, and for someone in apathy, silence may be the feature. Flagging the conflict rather than quietly resolving it.
06 · Who is this actually for?
"People in deep apathy" is a population that, almost by definition, does not download self-improvement apps. The people who will use Rise daily are probably already above the line. That's not fatal, but it changes the marketing entirely.
Sources
Every factual claim above resolves here. Accessed 16 July 2026.
- USPTO Reg. No. 4,086,310 — MAP OF CONSCIOUSNESS, Serial 85172946. Institute for Spiritual Research, Inc. Filed 2010-11-09, registered 2012-01-17, status "Registered and Renewed" 2021-07-01. Via Justia Trademarks and Trademark Elite.
- Veritas Publishing — Copyright & Trademark Policy. veritaspub.com/copyright
- Schwartz SA, Utts J, Spottiswoode SJP, et al. (2014) "A double-blind, randomized study to assess the validity of applied kinesiology (AK) as a diagnostic tool and as a nonlocal proximity effect." Explore (NY) 10(2):99–108. PubMed 24607076 · DOI 10.1016/j.explore.2013.12.002
- Jensen AM, Stevens RJ, Burls AJ. (2016) "Estimating the accuracy of muscle response testing: two randomised-order blinded studies." BMC Complement Altern Med 16:492. PMC5131520
- Jensen AM, Stevens RJ, Burls AJ. (2025) "Exploring the variation in muscle response testing accuracy through repeatability and reproducibility." PLoS One 20(7):e0326208. PMC12237029
- Lüdtke R, Kunz B, Seeber N, Ring J. (2001) "Test-retest-reliability and validity of the Kinesiology muscle test." Complement Ther Med 9(3):141–145. PubMed 11926427
- Columbia Pacific University — closure by permanent injunction, Marin County Superior Court (Judge Lynn Duryee), 2 Dec 1999; appeal lost 2000. Court findings included failure to meet requirements for issuing PhD degrees. Wikipedia · GetEducated degree-mill list · GAO-04-771T
- Hawkins DR. (1995) Qualitative and Quantitative Analysis and Calibration of the Levels of Human Consciousness. Doctoral dissertation, Columbia Pacific University. Open Library
- Veritas Publishing — Map of Consciousness®. Trademark 4,086,310; copyright TX 8-895-484; "over 250,000 calibrations spanning 30 years." veritaspub.com/map-of-consciousness · Official bio
- Hawkins D, Pauling L, eds. (1973) Orthomolecular Psychiatry: Treatment of Schizophrenia. W.H. Freeman. Internet Archive
- Dwyer B, Mikkelson J, Burns J, et al. (2025) "Mental Health Apps and Crisis Support: Exploring the Impact of 988." Psychiatric Services, Oct 2025. n=302. PubMed 40836663 · DOI 10.1176/appi.ps.20240485
- Soares JR, Stieven FF, Rocha CSS, Miranda IF. (2025) "Reliability of Manual Muscle Testing in Applied Kinesiology: A Systematic Review." J Manipulative Physiol Ther 48(6-9):862–870. PubMed 41236460
- American Psychiatric Association (1973) Task Force Report 7: Megavitamin and Orthomolecular Therapy in Psychiatry. APA (PDF) · Rebuttal: Hoffer, Am J Psychiatry 135(10):1252
- Alliance of the Orders of Saint John of Jerusalem, the five mutually recognised orders; all others described as "self-styled." Alliance · Self-styled order
- Haas M, Cooperstein R, Peterson D. (2007) "Disentangling manual muscle testing and Applied Kinesiology." Chiropractic & Osteopathy 15:11. PMC2000870
- Ideomotor effect — Carpenter WB (1852), "On the Influence of Suggestion in Modifying and Directing Muscular Movement"; Faraday M (1853), "Experimental Investigation of Table-Moving," Athenaeum. Modern review: Shin YK, Proctor RW, Capaldi EJ (2010), Psychological Bulletin 136(6):943–974. Overview · DOI 10.1037/a0020541
- Burgess CA, Kirsch I, Shane H, et al. (1998) "Facilitated communication as an ideomotor response." Psychological Science 9(1):71–74. DOI 10.1111/1467-9280.00013
- Apple App Store Review Guidelines — verified across three versions (June 2025 PDF, Feb 2026 PDF, live text last updated 8 June 2026). Zero occurrences of suicide / self-harm / crisis / hotline / mental health. Live guidelines
- Apple — updated age ratings, announced 24 July 2025; compliance deadline 31 Jan 2026. Tiers 4+, 9+, 13+, 16+, 18+. Announcement · Values & definitions
- FDA (2026) General Wellness: Policy for Low Risk Devices. Issued 6 Jan 2026, superseding the 2019 edition. FDA (PDF)
- FDA (2022) Policy for Device Software Functions and Mobile Medical Applications. Appendix B, item 1 — enforcement discretion for coping-skill software for diagnosed depression, anxiety, PTSD. FDA (PDF)
- Moodfit (Roble Ridge Software LLC). Team size and unfunded status per Tracxn [analyst estimate]. Store metrics from Apple lookup API and Play. Free-tier change proven via Wayback 2026-02-14 vs current. Note: the widely-cited "$780K raised" figure belongs to an unrelated MENA interior-design company of the same name. Not this app.
- Stoic (Stoic app inc.). Kraków HQ, team of 9, YC S19 per Y Combinator — note this contradicts Crunchbase/Tracxn, which list San Francisco. Store metrics from Apple lookup API and Play. iCloud-only sync and "cannot access or recover your data" from their own help docs. The "3+ million users" figure is a self-reported marketing claim; observable reach is 100K+ Play installs and 35K iOS ratings.
- Abraham-Hicks app status — both store links on abraham-hicks.com return HTTP 404; Apple lookup id411500177 returns resultCount 0 across 9 country stores. Manifest's $3.4M a16z Speedrun round: TechCrunch, Oct 2024. The Path's $14.3M clinical-AI-therapy round: TechCrunch, May 2026. Store metrics via iTunes Search/Lookup API, retrieved 2026-07-16.
- Spiral Dynamics / Integral app inventory — zero Spiral Dynamics apps on either store (iTunes Search API across 6 queries; Google Play). Integral Life id1596743901: 205 US ratings, last updated 2024-06-10; Android package delisted (HTTP 404, verified 2026-07-16). Also of note for any future framework play: all three of Integral Institute's "AQAL" trademarks are DEAD (abandoned 2006, 2008, 2010), while NVC Consulting's SPIRAL DYNAMICS mark (Reg. 4078926, renewed 2023) explicitly covers mobile assessment software.
- Blanchard M, Farber BA. (2020) "It is never okay to talk about suicide: Patients' reasons for concealing suicidal ideation in psychotherapy." Psychotherapy Research 30(1):124–136. PubMed 30409079
- Louzon SA, Bossarte R, McCarthy JF, Katz IR. (2016) "Does Suicidal Ideation as Measured by the PHQ-9 Predict Suicide Among VA Patients?" Psychiatric Services 67(5):517–522. 447,245 assessments. PubMed 26766757. PPV 0.26% derived in McCusker, Psychiatr Serv 2016;67(9):1042 and conceded in the authors' reply.
- McHugh CM, Corderoy A, Ryan CJ, Hickie IB, Large MM. (2019) "Association between suicidal ideation and suicide: meta-analyses of odds ratios, sensitivity, specificity and positive predictive value." BJPsych Open 5(2):e18. PMC6401538. Note the symmetry: ~60% of people who die by suicide had not expressed ideation earlier — ideation is a poor rule-out test too.
- NICE (2022) Self-harm: assessment, management and preventing recurrence. NICE guideline NG225, published 7 Sep 2022, §1.6.1–1.6.5. nice.org.uk/guidance/ng225
- 988 Suicide & Crisis Lifeline Suicide Safety Policy, effective 27 Dec 2022, §1.3.2–1.3.3. PDF
- Pisani AR, Murrie DC, Silverman MM. (2016) "Reformulating Suicide Risk Formulation: From Prediction to Prevention." Academic Psychiatry 40(4):623–629. PubMed 26667005
- PHQ-9 — "Copyright Pfizer Inc. No permission required to reproduce, translate, display, or distribute." Released without restriction 2010. phqscreeners.com
- C-SSRS licensing conflict — Columbia: "You do not need special permission… [to] embed the Columbia Protocol in your electronic health record keeping systems." versus Clario: "exclusive license agreement for the electronic implementations of this scale" — $40,000 start-up, $4 per administration. Copyright is held by the Research Foundation for Mental Hygiene, not Columbia. Also see Giddens, Sheehan & Sheehan 2014, an unrebutted (but conflicted) psychometric critique.
- Lieberman MD, Eisenberger NI, Crockett MJ, et al. (2007) "Putting Feelings Into Words: Affect Labeling Disrupts Amygdala Activity in Response to Affective Stimuli." Psychological Science 18(5):421–428. N=30. PDF. Note: no self-report distress measure appears anywhere in the paper, and every labelling condition increased amygdala activity versus the shape-match baseline — affect labelling simply increased it least.
- Lieberman MD, Inagaki TK, Tabibnia G, Crockett MJ. (2011) "Subjective Responses to Emotional Stimuli During Labeling, Reappraisal, and Distraction." Emotion 11(3):468–480. PMC3444304. Labelling 6.64→6.25 on a 9-point scale. Reappraisal beat labelling.
- Kircanski K, Lieberman MD, Craske MG. (2012) "Feelings Into Words: Contributions of Language to Exposure Therapy." Psychological Science 23(10):1086–1091. N=88. PMC4721564. Skin conductance improved (d=0.64–0.85); self-reported fear did not differ between groups.
- Behavioural activation evidence — Dimidjian et al., JCCP 2006;74(4):658–670 (N=241; BA/ADM bioequivalence p>99.1%). COBRA: Richards et al., The Lancet 2016;388:871–880, N=440, non-inferior to CBT. Cochrane: Uphoff et al. 2020, CD013305, 53 RCTs, 5,495 participants, BA vs CBT RR 0.99. But the smallest tested unit is a single 60-minute session; no study tests a micro-action. Also: Huguet et al., PLoS ONE 2016;11(5):e0154248 — of 117 apps, median BA fidelity 18.75%, zero with published efficacy studies.
- Kashdan TB, Barrett LF, McKnight PE. (2015) "Unpacking Emotion Differentiation." Current Directions in Psychological Science 24(1):10–16. PDF. Verbatim: "researchers must assess what is being felt without using prompts with a closed-ended list of emotion-word labels." The authors also concede the mechanism "await[s] scientific testing."
- Mamat Z, Anderson MC. (2023) "Improving mental health by training the suppression of unwanted thoughts." Science Advances 9:eadh5292. N=120, 16 countries. PMC10511195. Rebound in 1 of 120. Largest gains in high trait anxiety and probable PTSD. Cultural bound on expressive suppression: Soto et al., Emotion 2011;11(6):1450–1455.
- Kuppens P, Tuerlinckx F, Russell JA, Barrett LF. (2013) "The Relation Between Valence and Arousal in Subjective Experience." Psychological Bulletin 139(4):917–940. 8 datasets. PDF. Note the author list — Russell built the circumplex; Barrett co-authored core affect. Verbatim: "This casts doubt on the existence of a static, lawful relation between valence and arousal."
- Judd LL, Schettler PJ, Coryell W, Akiskal HS, Fiedorowicz JG. (2013) "Overt Irritability/Anger in Unipolar Major Depressive Episodes." JAMA Psychiatry, Nov 2013. N=536, NIMH Collaborative Depression Study, up to 31 years of follow-up. PubMed 24026579. Verbatim: anger is "a highly prevalent clinical marker of a more severe, chronic, and complex depressive illness."
- Jha MK, Minhajuddin A, South C, Rush AJ, Trivedi MH. (2019) "Irritability and Its Clinical Utility in Major Depressive Disorder." Am J Psychiatry 176(5):358–366. CO-MED N=431; replication N=163. PubMed 30922100. A one-SD greater reduction in irritability by week 4 → 1.73× higher remission at week 8.
- Mittal V, Brown WA, Shorter E. (2009) "Are Patients With Depression at Heightened Risk of Suicide as They Begin to Recover?" Psychiatric Services. PMC3712978. Verbatim: "As superficially appealing as the long-held mobilization-of-energy hypothesis is, it has little in the way of evidence to substantiate it."
- Astill Wright L, et al. (2026) "Mood Monitoring, Mood Tracking, and Ambulatory Assessment Interventions in Depression and Bipolar Disorder: Systematic Review and Meta-Analysis of RCTs." JMIR Ment Health 13:e84020. 8 RCTs, 1,230 participants. PMC12779106. Verbatim: mood monitoring interventions "do not increase or decrease mood symptoms."
- Bakker D, Kazantzis N, Rickwood D, Rickard N. (2018) "Development and pilot evaluation of smartphone-delivered cognitive behavior therapy strategies for mood- and anxiety-related problems: MoodMission." Behav Res Ther 109:75–83. N=226, 30 days. PubMed 30125790. Only the two CBT apps reduced depression; the tracking-only app did not. The mediator was coping self-efficacy, not emotional self-awareness.
- Astill Wright L, Monk-Cunliffe J, Guo B, Morriss R. (2025) "Adverse Events of Mood Monitoring and Ambulatory Assessment in Depression and Bipolar Disorder." JMIR Ment Health 2025;1:e79500. 77 studies, 16,165 participants. PMC12548826. Only 19% reported adverse events; only 4% used validated harm instruments.
- Nolen-Hoeksema S, Wisco BE, Lyubomirsky S. (2008) "Rethinking Rumination." Perspectives on Psychological Science 3(5):400–424. PDF. The standard rumination induction asks participants to "focus on the meanings, causes, and consequences of their current feelings" for 8 minutes, and significantly increases dysphoric mood in dysphoric participants but not in nondysphoric ones. See also Moberly & Watkins, J Abnorm Psychol 2008;117(2):314–323 (N=93, 3,992 occasions; bidirectional spiral).
- MONARCA trials — Faurholt-Jepsen M, et al. (2015) Psychol Med 45(13), N=78: "a tendency towards more sustained depressive symptoms in the intervention group" (B=2.02, 95% CI −0.13 to 4.17, p=0.066). MONARCA II (2019/2020) Psychol Med 50(5):838–848, N=129: primary outcomes null, but "patients in the intervention group had higher risk of depressive episodes" while simultaneously reporting improved quality of life and reduced perceived stress. See also Linardon et al., npj Digital Medicine 2024;7:363 — trials were significantly more likely to report adverse events when the app included mood-monitoring features (p=0.016).
- Mor N, Winquist J. (2002) "Self-focused attention and negative affect: a meta-analysis." Psychological Bulletin 128(4):638–662. 226 effect sizes. Rumination yields stronger effects than non-ruminative self-focus, and relations are stronger in clinical samples. Pooled effect sizes unverified, not in the public abstract, full text paywalled. Do not cite a number.
- India — Digital Personal Data Protection Act, 2023 (Act 22 of 2023), §3(c)(i) domestic-purpose exclusion; §2(i) Data Fiduciary (no receipt/custody element); §9(2) child well-being (non-derogable, not exemptible via the Fourth Schedule); Schedule Sl. 3 penalty ceiling ₹200 crore. Gazette (MeitY) · indiacode mirror · DPDP Rules 2025. Note the timing: §§3–17 and §44(2) are NOT yet in force — commencement notification G.S.R. 843(E) puts them in an 18-month tranche expiring ~13–14 May 2027. Until then IT Act §43A and the SPDI Rules 2011 remain live, and those do classify "mental health condition" as sensitive (Rule 3(iii)) — but §43A's custodial gates ("possessing, dealing or handling… in a computer resource which it owns, controls or operates") are ones an on-device app cleanly fails to trigger. Unlike GDPR Recital 18, the DPDP Act contains no clawback pulling tool-providers back into scope. No Indian case law, MeitY guidance, or Board decision exists on any of this. Not legal advice.
- EU — GDPR & ePrivacy. Mood diary named as health data: Art. 29 WP, mHealth Annex (5 Feb 2015), fn. 5 — an app combining years of records "as well as a mood diary" processes health data, and "not only the conclusions and inferences, but also the raw data will be considered health data." GDPR Art. 4(15), Recital 35 ("independent of its source"), Art. 9(1). Controller analysis: Art. 4(7); EDPB Guidelines 07/2020 v2.0 (software choice is a non-essential mean); Jehovan todistajat C-25/17 ¶68 ("for his own purposes") and Fashion ID C-40/17 ¶74. ePrivacy: EDPB Guidelines 2/2023 v2.0 (7 Oct 2024) ¶15 (network not required — device need only be "connectable") and ¶44 (using information "provided by the users themselves" is not "gaining access" "as long as the information does not leave the device"); Dir. 2009/136/EC Recital 65 (USB-key example). Two flags: the Art. 5(3) storing limb is genuinely unresolved — the EDPB never addresses a self-contained app — and Art. 5(3) is a Directive, so there are 30 national transpositions and no pan-EU answer. Note also the ePrivacy Regulation was withdrawn (Feb 2025); the Digital Omnibus (proposed Nov 2025, not adopted) would move these rules into the GDPR, which would help us. Not legal advice.
- HIPAA — does not apply. 45 CFR 160.102(a)(3) requires a provider who transmits health information electronically in connection with a covered transaction — an app with no network calls conducts none of the twelve. Not a business associate either: no covered entity exists. OCR, "Health App Use Scenarios & HIPAA" (Feb 2016), Scenario 1 addresses this exact fact pattern — consumer populates a health app with her own information — and answers: "No. Developer is not creating, receiving, maintaining or transmitting protected health information on behalf of a covered entity."
- FTC Health Breach Notification Rule, 16 CFR Part 318, as amended 89 FR 47028 (30 May 2024, effective 29 July 2024). §318.2 defines health care services or supplies to expressly include a "mobile application… that provides mechanisms to track… mental health" — so we are a covered health care provider and the mood data is covered information. The only element that fails is personal health record: "technical capacity to draw information from multiple sources." The trap: the FTC's 2021 Policy Statement counts "dates from your phone's calendar" as a second source — no network involved. The 2024 preamble adopts a near-identical example to this product: "a depression management app that accepts consumer inputs of mental health states and has the technical capacity to sync with a wearable sleep monitor is a personal health record, even if some customers choose not to sync" — and the Commission expressly "declines to exempt apps and services where there are available but unused or unpublicized APIs or integrations" or those in beta. Favourable authority: preamble Example 2 holds a symptom tracker is not a PHR "if the consumer is its only source of information." Flagged: the FTC has never addressed a local-only architecture — a full-text search of the 2024 rule returns zero hits for on-device / locally / never receives / no data leaves. This is an application of the PHR definition to a fact pattern the Commission has not considered. State law (Washington My Health My Data, Nevada SB 370) not researched and is a live gap. Not legal advice.
- Nook EC, Satpute AB, Ochsner KN. (2021) "Emotion Naming Impedes Both Cognitive Reappraisal and Mindful Acceptance." Affective Science 2(2):187–198. Study 1 N=80, Study 2 N=60. PMC9383041. Regulate vs Name+Regulate d = −1.21. Verbatim: participants who named their emotions before reappraising "reported feeling worse"; naming may "crystallize" one's affective experience and make it "more resistant to modification." Replicated: Ariely, Mokady, Reggev & Anholt (2026), Affective Science 7(2):282–292, PMC13269579, N=226 — results "mirrored those of Nook et al. (2021), with affect labeling reducing the effectiveness of reappraisal"; their own delayed-benefit hypothesis failed. Do not overstate: naming alone was not significant (p=.293) — the harm is interference with an active regulation attempt.
- Niles AN, Craske MG, Lieberman MD, Hur C. (2015) "Affect labeling enhances exposure effectiveness for public speaking anxiety." Behav Res Ther 68:27–36. N=100 analysed. PubMed 25795524. Self-report null (ps > .196). The dose–response runs backwards, verbatim: "Contrary to hypotheses, participants who used fewer affect labels during exposure showed greater improvement in self-reported public speaking anxiety than participants who used more affect labels during exposure." And no meta-analysis of affect labelling has ever been published — triangulated across PubMed, Europe PMC, OpenAlex, the 2026 Trends in Cognitive Sciences review (zero occurrences of "meta-anal"), and a 2026 PROSPERO-registered systematic review (Shukla & Mishra, Current Psychology 45:683) which deliberately declined to pool.
- Emotion granularity — the causal evidence, or absence of it. Four randomised studies raise the differentiation index; none shows it helps anyone. Mikkelsen et al. 2021, Anxiety Stress Coping 34(4):479–485 (PMC8364870): index up (η²=0.21) but "improvements in negative emotion differentiation were not associated with changes in distress." Guendelman et al. 2025, Front Hum Neurosci 19:1515334: index up (p=.04) but "changes in negative and positive ED did not correlate significantly with mental health outcomes" — all five null. Widdershoven et al. 2019, J Affect Disord 244:71–77: couldn't test it, and the "intervention" is six weeks of practice with the measuring instrument — the authors concede "measurement reactivity is important to consider." Vedernikova et al. 2021, Front Psychol 12:703757: well-being outcomes collected, not reported ("very inconsistent"). The measure itself is in trouble. Ecker et al. (2026), Collabra: Psychology 12(1):159939, multiverse analysis, 192 universes × 3 datasets: the granularity–depression correlation was "not robust in any of the data sets"; in Study 2 "all correlations… were unexpectedly positive, with 40% being significant." Dejonckheere et al. (2019), Nature Human Behaviour 3(5):478–491, n=1,777: once overlap with mean affect is controlled, differentiation's "added value is no longer significant." Erbas et al. (2022), Assessment 29(4):700–716: the index "is equivalent to Cronbach's alpha" — it rises mechanically with how many emotion words you offer. Meta-analytic ceiling r = −0.14 (Hong 2025, k=16, n=2,515); O'Toole et al. (2020), Emotion Review 12(1):23–38, call the effects "negligible."
- Vine V, Bernstein EE, Nolen-Hoeksema S. (2019) "Less is more? Effects of exhaustive vs. minimal emotion labelling on emotion regulation strategy planning." Cognition & Emotion 33(4):855–862. N=82, randomised. PubMed 29912630. Verbatim: "Minimal (vs. exhaustive) emotion labelling promoted higher subjective emotional clarity… minimal emotion labelling prompted more plans for problem solving." Rise's two-tap, one-pick check-in is the minimal condition; How We Feel's 144-word Mood Meter is the exhaustive one.
- The "$150 → $500–1,000 CAC" stat — traced to origin, and it isn't research. Rock Health, "2022 year-end digital health funding" (9 Jan 2023) prints it inside quotation marks and hyperlinks "rocketed" to Business Insider (1 Dec 2022). Three defects. (1) The quoted sentence appears nowhere in the BI article — Rock Health quote-marked its own paraphrase. (2) BI's actual text: "Anh estimated that the cost of acquiring a customer for direct-to-consumer healthcare companies ranged from $500 and $1,000, up from around $150 in 2018" — Dr. Ho Anh, a Cerebral cofounder, speaking at a Jefferies investor event in May 2022. No study, no dataset, no method. (3) Scope drift: BI said "direct-to-consumer healthcare companies"; Rock Health narrowed it to "D2C digital health startups"; neither said mental health apps. Anh was an interested party — Cerebral was under DOJ investigation at the time. Do not cite as Rock Health data.
- "10,000–20,000 mental health apps" — the citation chain collapses. The 20,000 is a multiplication: Schueller et al., J Med Internet Res 2018;20(6):e10141 (PMC6018235) computes 325,000 × 7% = 22,750 — where 325,000 is a vendor press release and the 7% traces to a paper (Van Ameringen 2017) whose abstract contains no such figure. The ubiquitous "10,000–20,000" range originates in APA Monitor (Jan 2021): "Mental health-related self-help apps now number somewhere between 10,000 and 20,000, estimates Stephen Schueller, PhD" — an unsourced verbal estimate in a magazine interview. Deloitte's TMT Predictions 2022 then cites the APA Monitor piece — and everyone cites Deloitte. An interview quote acquires a Big Four letterhead in one hop. And Torous himself, the researcher credited with the 10,000, on the record: "There's no exact number… It's clearly not an exact number… certainly it's more than a thousand. It's less than 20,000." Nobody has counted.
- BetterHelp / Teladoc (NYSE: TDOC) and Talkspace (NASDAQ: TALK) — audited SEC filings. The only auditable paid-acquisition economics at scale in this category. Teladoc third-party advertising expense (10-K footnote: "predominately relate to the BetterHelp segment"): 2020 $165.0M · 2021 $297.0M · 2022 $503.9M · 2023 $613.9M · 2024 $594.4M · 2025 $545.7M. BetterHelp segment: revenue $1,133.6M (2023) → $1,040.7M (2024) → $950.4M (2025); advertising as % of revenue 47.8% → 53.7% → 54.6%; adjusted EBITDA $136.2M → $77.8M → $41.9M (−69% in two years). Average monthly paying users 457K (2023) → 405K (2024) → 386K (2025) → 361K (Q1 2026, −9% YoY). FY2025 10-K. CFO Mala Murthy, Q2 2024 call: "we saw a double-digit percentage increase in customer acquisition costs in May" and "our scale makes us the largest advertiser of virtual mental health." Note: widely-repeated claims that BetterHelp's CAC "doubled" are false — she said double-digit. Talkspace: advertising $31.5M (2020) → $69.3M (2021), +120%, while consumer active members fell 29,500 → 23,800; by 2024 advertising expense ($26.1M) exceeded total consumer revenue ($24.8M). TALK FY2024 10-K. Neither company has ever disclosed a CAC figure.
- Distribution and attrition. Google Play's own published download brackets via AppBrain (n=1,890,769, 16 Jul 2026): 52.1% of apps have fewer than 1,000 lifetime downloads; 74.8% fewer than 10,000; only 3.4% ever pass 1M. Health & Fitness: 90,930 apps, of which only 7.9% ever pass 50K downloads. Discovery: Apple's own figure — "70% of App Store visitors use search to discover apps"; "almost 65% of downloads happen directly after a search" (ads.apple.com, worldwide 2022) — corroborated independently by Sensor Tower (search 65%; non-games 69%). Supply is accelerating: app releases up 60% YoY in Q1 2026, +80% on iOS; April 2026 +104% — attributed to AI-assisted development (Appfigures via TechCrunch). Attrition — Larsen ME, Nicholas J, Christensen H (2016), JMIR mHealth uHealth 4(3):e96, DOI 10.2196/mhealth.6020: daily store tracking over 9 months found "a clinically relevant app for depression becoming unavailable to download every 2.9 days"; ~25% of Android mental health apps vanished within 9 months. Of 982 apps returned for "depression", only 35.3% were clinically relevant; of those, 9 (2.6%) offered any evidence of effectiveness and only 3 cited a published study. Caveat: this is the best attrition evidence available and it is a decade old. Never replicated at scale.
- Lagan S, Sandler L, Torous J, et al. (2021) "Evaluating evidence-based content, features of therapeutic components, and support of mental health apps." Acta Psychiatr Scand 144(2):201–210. 29,190 data points across 278 apps. PubMed 33835483. The finding that is the actual wedge, verbatim: app stars and downloads — "even for the most popular apps by these metrics" — "did not correlate with more clinically relevant metrics related to privacy/security, effectiveness, and engagement." Also: only 36.4% of apps were updated within a 100-day window; 7.5% had not been updated in four years. See also Carlo AD, et al. (2019), npj Digital Medicine 2:54, DOI 10.1038/s41746-019-0129-6: of the top 25 behavioral health apps in the world, 19 had fewer than 100,000 Google Play monthly actives, and Google Play had no app above 1M MAU. The ceiling is far lower than download counts imply.
- Connecticut AG — live investigation into a consumer health app. 2025 CTDPA Enforcement Report (published 5 Feb 2026): an investigation into a fertility-tracking app opened because its "privacy notice failed to recognize Connecticut's heightened consumer health data protections"; the AG "tested their app on both iOS and Android devices to review data flows"; and processing "voluntarily shared" consumer health data is unlawful where companies "do not inform consumers about the heightened risks of harm." Conn. Gen. Stat. § 42-515(9), as amended by PA 25-113 § 5 in force 1 July 2026, now reads "consumer health data means any personal data that a controller uses to identify a consumer's physical or mental health condition, [or] diagnosis or status" — "or status" is two weeks old and broadens the definition beyond diagnosis. CHD provisions have had no size threshold since 1 Oct 2023 (§ 42-526(a)(2), "Notwithstanding section 42-516"); the CT AG confirms coverage applies "regardless of their size."
- US state consumer-health-data laws — the size-threshold map. CCPA/CPRA (Civ. Code § 1798.140): mood data is "sensitive personal information" under (ae)(2)(B), but the § 1798.140(d)(1) thresholds turn on "buys, sells, or shares" — structurally impossible with no network calls, at any user count. Revenue prong is CPI-adjusted to $26,625,000 (eff. 1/1/2025; adjustments only in odd years, next 1/1/2027). Washington MHMDA (RCW 19.373.010): no size threshold. "Collect" (5) means "to buy, rent, access, retain, receive, acquire, infer, derive, or otherwise process… in any manner"; "process" (20) is "any operation." Neither names an actor or a location. Washington is the weakest ground because it has no "use" element — CHD is defined by what the data "identifies", a property of the data, unlike Nevada and Connecticut which both require a regulated entity to "use it to identify." Do not port an NV/CT conclusion into WA. "Small business" was never an exemption — it only shifted the compliance date to 30 June 2024, long past. Private right of action via RCW 19.373.090 → the Consumer Protection Act, but under Hangman Ridge a plaintiff must still prove injury to business or property. MHMDA remains judicially untested — Maxwell v. Amazon, the first class action, was voluntarily dismissed June 2025 with no merits ruling. Nevada NRS 603A.400–.550: "collect" is word-for-word identical to Washington's, but narrower via "uses to identify", and the private action is barred. Vermont Act 145: no threshold, effective 1 Jan 2028 — calendar it.
- California CMIA — the statute that deems an app a health care provider. Cal. Civ. Code § 56.06(b): "Any business that offers software or hardware to consumers, including a mobile application… designed to maintain medical information… for purposes of allowing the individual to manage the individual's information… shall be deemed to be a provider of health care subject to the requirements of this part." No revenue threshold, no volume threshold. § 56.36(b) provides nominal damages of $1,000 where "it is not necessary that the plaintiff suffered or was threatened with actual damages." Three off-ramps hold for the baseline app: (1) "medical information" requires information "in possession of or derived from a provider of health care" — we possess nothing (though note a genuine circularity between §§ 56.05(j)(1) and 56.06 that no case law resolves); (2) § 56.06(f) is limited to "medical information disclosed to the business" — nothing is; (3) § 56.36(b) requires a record "negligently released" — an app with no network calls cannot release anything. And a fourth, which is the cheapest control in this dossier: § 56.05(l) "mental health digital service" is a three-part conjunctive test — the app must collect mental health information AND market itself as facilitating mental health services AND use the information to facilitate them. A tracker marketed as journaling or self-knowledge fails prong two and escapes § 56.06(d) entirely. It is one landing-page rewrite away from being lost. Off-ramps 2 and 3 collapse the moment any analytics ships.
- Retention — the correction. Baumel A, Muench F, Edan S, Kane JM. (2019) "Objective User Engagement With Mental Health Apps." J Med Internet Res 21(9):e14567, DOI 10.2196/14567 — 93 apps; median D30 3.3%. But 3.3% is approximately the all-app median. AppsFlyer (Q3 2021, US): all-category D30 ~3.55%; Social 2.45% and Education 1.69% retain worse than Health & Fitness. UXCam 2026: all-app median ~4%, H&F median 5%. And Baumel's own by-type data favours the tracker form factor: peer support 8.9% > trackers 6.1% > mindfulness/meditation 4.7% > breathing 0.0%. Daylio retains D1 65.6% / D7 45.8% / D30 37.7% (data.ai 2023 via Naavik) — Naavik's own words: "Daylio manages to retain users long-term to a degree none of the other apps comes close to." Two caveats before citing Baumel at all: it defines retention against users who installed and opened, so tire-kickers are already excluded — the denominator rebuttal doesn't work; and it is itself panel data (SimilarWeb Pro), Android-only, 2017–18. It remains the field's benchmark in 2026 (Torous et al., World Psychiatry 2025) — which is itself a finding: seven years on, nothing better has displaced it, because the field has no standardised engagement metric.
- Linardon J, Torous J, Firth J, et al. (2024) "Current evidence on the efficacy of mental health smartphone apps for symptoms of depression and anxiety." World Psychiatry 23(1):139–149. 176 RCTs. DOI 10.1002/wps.21183. Depression g = 0.28, anxiety g = 0.26, social anxiety g = 0.52, OCD g = 0.51; NNT ≈ 11–12. Critically: mood monitoring features specifically are associated with LARGER effect sizes. This does not contradict Astill Wright 2026 (8 RCTs, mood monitoring null) — it reframes it. Wright tested mood monitoring as the intervention; Linardon tested apps containing mood monitoring. Tracking alone does nothing; tracking that triggers something works. Note also Baumel, Edan & Kane (2019), Transl Behav Med 9(6):1020: trials with proactive recruitment reported usage 4.06× higher than real-world usage of the same programs — divide any RCT engagement figure by ~4 before believing it.
- Wasil AR, Weisz JR, DeRubeis RJ, et al. (2021) "Estimating the real-world usage of mobile apps for mental health: development and application of two novel metrics." World Psychiatry 20(1):137–138. PMC7801857. Mood tracking: top 3 apps = 79.2% of MAU (MSI-3); 6 apps reach 90% (NNR-90). Verbatim: "In six of the eight categories, the top three apps were responsible for more than 50% of MAUs." Median MSI-3 across categories = 71.1%. Companion paper (World Psychiatry 2020, DOI 10.1002/wps.20757): Headspace and Calm alone ≈ 90% of total mental-health-app MAU. This — not the app count — is the red-ocean proof.
- Unit economics and the observed ceiling. RevenueCat State of Subscription Apps 2026 — 115,000+ apps, $16B revenue, 1B+ transactions; transaction-derived, the best data that exists. Health & Fitness is the best-converting non-gaming category and still converts only 2.9% of downloads to paid (D35); Year-1 realised LTV per payer $35.64 — 11% BELOW one year of list price ($39.94), and only 1.47× the Month-1 figure ($24.23). Median subscription app: ~$72/month one year post-launch; 95.4% never reach $10K MRR; apps launched 2025+ capture 3% of all revenue while 14,700+ new subscription apps launch monthly. Annual Year-1 cancellation worsened ~56% → ~72% in one year. AI apps churn 30% faster and retain 36% worse over 12 months (+41% revenue/payer). Daylio ≈ $150K/mo ≈ $1.8M/yr [panel estimate] after ~10 years and 19.2M downloads — the observed ceiling for a pure-play mood tracker. Bottom-up ($1.03 Y1 revenue per download at median execution) and top-down (mood tracking as a slice of a Meditation & Sleep category that shrank $29M in 2025) converge on $150K–$2M/yr.
- Gamification and reminders — both fail. Six SL, et al. (2021), JMIR Mental Health, 38 studies, n=8,110: gamification → adherence β = −1.93, SE 2.28, P = .40 — no effect. npj Digital Medicine (2025), 92 RCTs, n=16,728: "no significant association was found between persuasive principles and either efficacy or engagement." And the head-to-head panel data inverts the intuition: Daylio (no gamification) D30 37.7% vs Finch (heavy gamification) D30 18.2% — from an article about gamification. Reminders: JMIR Mental Health, 12 Jan 2026, DOI 10.2196/83765, 77 studies, 17,123 participants — pooled adherence 64%, attrition 28%, and reminders DECREASED adherence and INCREASED attrition.